Compare MAKO & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MAKO | SPRY |
|---|---|---|
| Founded | N/A | 2015 |
| Country | Canada | United States |
| Employees | 30 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 695.3M | 796.4M |
| IPO Year | N/A | 2020 |
| Metric | MAKO | SPRY |
|---|---|---|
| Price | $7.73 | $8.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | 124.4K | ★ 1.9M |
| Earning Date | N/A | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | N/A | $87.40 |
| Revenue Next Year | N/A | $81.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.10 | $6.66 |
| 52 Week High | $8.17 | $18.63 |
| Indicator | MAKO | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 39.90 | 43.72 |
| Support Level | $7.10 | $7.41 |
| Resistance Level | N/A | $8.61 |
| Average True Range (ATR) | 0.36 | 0.58 |
| MACD | 0.01 | -0.18 |
| Stochastic Oscillator | 57.94 | 21.66 |
Mako Mining Corp is a gold mining, development, and exploration firm. The companies primary asset is the San Albino mine, an open-pit mine located in Nicaragua. In addition to its mining operation, the company continues to explore its other concessions in Nicaragua and Guyana.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.